Last October the FDA announced a public meeting on Patient-Focused Drug Development for fibromyalgia and invited input from patients. The meeting, originally set for December 10, 2013, has been rescheduled for March 26, 2014. They are still seeking input from FM patients. If you would like to attend the meeting, you can register to attend either in person or via Webcast.
Following is the FDA notice giving details of the meeting and links to register or submit comments:
On March 26, 2014, FDA is conducting a public meeting on Patient-Focused Drug Development for fibromyalgia. FDA is interested in obtaining patient input on the impact of fibromyalgia on daily life and patients’ views on currently available therapies to treat the condition. This is a rescheduling of the original December 10, 2013 meeting.
This website will be updated as additional meeting information becomes available.
Submitting comments to the docket:
In addition to providing input at the public meeting, patient stakeholders can provide their perspectives on the discussion questions through the public docket. The docket closes on May 26, 2014. To submit your comments, visit http://www.regulations.gov/#!documentDetail;D=FDA-2013-N-1041-0001.
Alternatively, you can fax or mail your comments. Fax comments to the Division of Dockets Management at 301-827-6870, or mail comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should include the docket number FDA-2013-N-1041.
“Public Meeting on Fibromyalgia Patient-Focused Drug Development
.” FDA Notice, January 23, 2014.